Delving into the Latest Updates on TB-D004C with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

TB D004C, TB-D004C, TBD004C

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Diabetes Mellitus, Type 2Diabetic Nephropathies

Inactive Indication-

Originator Organization

Shenzhen Turier Biotech Co., Ltd.

Active Organization

Shenzhen Turier Biotech Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价TB-D004C注射液在健康受试者单次皮下注射给药后以及在2型糖尿病受试者多次皮下注射给药后的安全性、耐受性及药代动力学特征。次要目的：评价TB-D004C注射液在健康受试者单次给药后的药效学特征；评价TB-D004C注射液在2型糖尿病受试者多次皮下注射给药后的药效学特征、胰岛素敏感性和β细胞功能。

[Translation]

Primary objectives: To evaluate the safety, tolerability, and pharmacokinetic profile of TB-D004C injection after a single subcutaneous dose in healthy subjects and after multiple subcutaneous doses in subjects with type 2 diabetes. Secondary objectives: To evaluate the pharmacodynamic profile of TB-D004C injection after a single dose in healthy subjects and to evaluate the pharmacodynamic profile, insulin sensitivity, and β-cell function of TB-D004C injection after multiple subcutaneous doses in subjects with type 2 diabetes.

Start Date-

Sponsor / Collaborator

Shenzhen Turier Biotech Co., Ltd.

100 Clinical Results associated with TB-D004C

Login to view more data

100 Translational Medicine associated with TB-D004C

Login to view more data

100 Patents (Medical) associated with TB-D004C

Login to view more data

100 Deals associated with TB-D004C

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	China	Shenzhen Turier Biotech Co., Ltd.	20 Aug 2025
Diabetic Nephropathies	Phase 1	China	Shenzhen Turier Biotech Co., Ltd.	20 Aug 2025